# Philippe Couratier

List of Publications by Year
in descending order



| 85 | 4,369 | 136885 | 114418 |
|---|---|---|---|
| papers | citations | 32 h-index | 63 g-index |

| 94 | 94 | 94 | 5031 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433. | 4.9 | 342 |
| 2 | Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. American Journal of Clinical Nutrition, 2001, 74, 328-334. | 2.2 | 304 |
| 3 | TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Annals of Neurology, 2009, 65, 470-473. | 2.8 | 278 |
| 4 | SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. Journal of Medical Genetics, 2010, 47, 554-560. | 1.5 | 266 |
| 5 | Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648. | 9.4 | 223 |
| 6 | Hypermetabolism in ALS: Correlations with Clinical and Paraclinical Parameters. Neurodegenerative Diseases, 2005, 2, 202-207. | 0.8 | 208 |
| 7 | Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. International Journal of Epidemiology, 2017, 46, dyw061. | 0.9 | 202 |
| 8 | Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156. | 4.9 | 175 |
| 9 | Ultrastructural PMP22 expression in inherited demyelinating neuropathies. Annals of Neurology, 1996, 39, 813-817. | 2.8 | 136 |
| 10 | High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 113-117. | 2.3 | 135 |
| 11 | Early Cognitive, Structural, and Microstructural Changes in Presymptomatic C9orf72 Carriers Younger Than 40 Years. JAMA Neurology, 2018, 75, 236. | 4.5 | 108 |
| 12 | The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 1-10. | 2.3 | 107 |
| 13 | Memantine in Behavioral Variant Frontotemporal Dementia: Negative Results. Journal of Alzheimer's Disease, 2011, 23, 749-759. | 1.2 | 107 |
| 14 | C9ORF72 Repeat Expansions in the Frontotemporal Dementias Spectrum of Diseases: A Flow-chart for Genetic Testing. Journal of Alzheimer's Disease, 2013, 34, 485-499. | 1.2 | 93 |
| 15 | Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. European Journal of Epidemiology, 2016, 31, 229-245. | 2.5 | 87 |
| 16 | Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurology, The, 2016, 15, 1217-1227. | 4.9 | 65 |
| 17 | Can Mortality Data Be Used to Estimate Amyotrophic Lateral Sclerosis Incidence?. Neuroepidemiology, 2011, 36, 29-38. | 1.1 | 61 |
| 18 | Phase angle is a prognostic factor for survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 273-278. | 2.3 | 60 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 1998, 154, 137-145. | 0.3 | 50 |
| 20 | Novel UBQLN2 mutations linked to amyotrophic lateral sclerosis and atypical hereditary spastic paraplegia phenotype through defective HSP70-mediated proteolysis. Neurobiology of Aging, 2017, 58, 239.e11-239.e20. | 1.5 | 50 |
| 21 | Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 88-93. | 2.3 | 49 |
| 22 | Specific psychological and behavioral symptoms of depression in patients with dementia. International Journal of Geriatric Psychiatry, 2010, 25, 1065-1072. | 1.3 | 49 |
| 23 | A dose-dependent increase of Tau immunostaining is produced by glutamate toxicity in primary neuronal cultures. Brain Research, 1992, 572, 242-246. | 1.1 | 46 |
| 24 | Age-specific ALS incidence: a doseâ€“response meta-analysis. European Journal of Epidemiology, 2018, 33, 621-634. | 2.5 | 46 |
| 25 | Estimation of the amyotrophic lateral sclerosis incidence by capture-recapture method in the Limousin region of France. Journal of Clinical Epidemiology, 2000, 53, 1025-1029. | 2.4 | 45 |
| 26 | Epidemiological evidence that physical activity is not a risk factor for ALS. European Journal of Epidemiology, 2014, 29, 459-475. | 2.5 | 44 |
| 27 | July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474. | 1.1 | 41 |
| 28 | Describing perceived stigma against Alzheimer's disease in a general population in France: the STIGâ€MA survey. International Journal of Geriatric Psychiatry, 2013, 28, 933-938. | 1.3 | 40 |
| 29 | Incidence of amyotrophic lateral sclerosis in the Limousin region of France, 1997â€“2007. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 216-220. | 2.3 | 39 |
| 30 | Population-Based Evidence that Survival in Amyotrophic Lateral Sclerosis Is Related to Weight Loss at Diagnosis. Neurodegenerative Diseases, 2016, 16, 225-234. | 0.8 | 39 |
| 31 | Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264. | 5.8 | 38 |
| 32 | Metabo-lipidomics of Fibroblasts and Mitochondrial-Endoplasmic Reticulum Extracts from ALS Patients Shows Alterations in Purine, Pyrimidine, Energetic, and Phospholipid Metabolisms. Molecular Neurobiology, 2019, 56, 5780-5791. | 1.9 | 34 |
| 33 | Tau antigenic changes induced by glutamate in rat primary culture model: A biochemical approach. Neuroscience Letters, 1992, 140, 206-210. | 1.0 | 33 |
| 34 | Structural, Microstructural, and Metabolic Alterations in Primary Progressive Aphasia Variants. Frontiers in Neurology, 2018, 9, 766. | 1.1 | 33 |
| 35 | ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Communications, 2020, 2, fcaa064. | 1.5 | 33 |
| 36 | Fatigue as the main presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy: a study of 11 cases. Journal of the Peripheral Nervous System, 2005, 10, 329-337. | 1.4 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | A Mutation that Creates a Pseudoexon in SOD1 Causes Familial ALS. Annals of Human Genetics, 2009, 73, 652-657. | 0.3 | 32 |
| 38 | Contribution of geolocalisation to neuroepidemiological studies: Incidence of ALS and environmental factors in Limousin, France. Journal of the Neurological Sciences, 2011, 309, 115-122. | 0.3 | 29 |
| 39 | Juvenile and adult-onset ALS/MND among Africans: incidence, phenotype, survival: A review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 276-283. | 2.3 | 29 |
| 40 | Management and therapeutic perspectives in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 263-276. | 1.4 | 29 |
| 41 | Predictors of Rapid Cognitive Decline in Patients with Mild-to-Moderate Alzheimer Disease: A Prospective Cohort Study with 12-Month Follow-Up Performed in Memory Clinics. Dementia and Geriatric Cognitive Disorders, 2018, 45, 56-65. | 0.7 | 29 |
| 42 | Liver X Receptor Genes Variants Modulate ALS Phenotype. Molecular Neurobiology, 2018, 55, 1959-1965. | 1.9 | 28 |
| 43 | Stratification of ALS patientsâ€™ survival: a population-based study. Journal of Neurology, 2016, 263, 100-111. | 1.8 | 27 |
| 44 | Current view and perspectives in amyotrophic lateral sclerosis. Neural Regeneration Research, 2017, 12, 181. | 1.6 | 26 |
| 45 | Stress oxydant et maladies neurodÃ©gÃ©nÃ©ratives. Nutrition Clinique Et Metabolisme, 2002, 16, 253-259. | 0.2 | 25 |
| 46 | Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme. BMJ Open, 2014, 4, e005528-e005528. | 0.8 | 25 |
| 47 | Hypermetabolism is a reality in amyotrophic lateral sclerosis compared to healthy subjects. Journal of the Neurological Sciences, 2021, 420, 117257. | 0.3 | 23 |
| 48 | Referral bias in ALS epidemiological studies. PLoS ONE, 2018, 13, e0195821. | 1.1 | 22 |
| 49 | A novel mutation of the C-terminal amino acid of FUS (Y526C) strengthens FUS gene as the most frequent genetic factor in aggressive juvenile ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 298-301. | 1.1 | 21 |
| 50 | Disease progression and survival in ALS: First multiâ€state model approach. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 224-229. | 2.3 | 20 |
| 51 | Genetic screening of ANXA11 revealed novel mutations linked to amyotrophic lateral sclerosis. Neurobiology of Aging, 2021, 99, 102.e11-102.e20. | 1.5 | 20 |
| 52 | Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSAâ€FLUO Trial. Movement Disorders, 2021, 36, 1704-1711. | 2.2 | 18 |
| 53 | Prognosis of ALS: Comparing data from the Limousin referral centre, France, and a Uruguayan population. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 355-360. | 2.3 | 17 |
| 54 | Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 519-527. | 1.1 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Pure cerebellar ataxia linked to large C9orf72 repeat expansion. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 301-303. | 1.1 | 15 |
| 56 | History and current difficulties in classifying inherited myopathies and muscular dystrophies. Journal of the Neurological Sciences, 2018, 384, 50-54. | 0.3 | 14 |
| 57 | Predictive factors for gastrostomy at time of diagnosis and impact on survival in patients with amyotrophic lateral sclerosis. Clinical Nutrition, 2020, 39, 3112-3118. | 2.3 | 14 |
| 58 | Characteristics and Prognosis of Oldest Old Subjects with Amyotrophic Lateral Sclerosis. Neuroepidemiology, 2017, 49, 64-73. | 1.1 | 13 |
| 59 | Resting energy expenditure equations in amyotrophic lateral sclerosis, creation of an ALS-specific equation. Clinical Nutrition, 2019, 38, 1657-1665. | 2.3 | 13 |
| 60 | Time-trend evolution and determinants of sex ratio in Amyotrophic Lateral Sclerosis: a doseâ€“response meta-analysis. Journal of Neurology, 2021, 268, 2973-2984. | 1.8 | 13 |
| 61 | The Effect of <scp>SMN</scp> Gene Dosage on <scp>ALS</scp> Risk and Disease Severity. Annals of Neurology, 2021, 89, 686-697. | 2.8 | 10 |
| 62 | Development and validation of an instrument to detect depression in nursing homes. Nursing homes short depression inventory (NHâ€sDI). International Journal of Geriatric Psychiatry, 2011, 26, 853-859. | 1.3 | 9 |
| 63 | Validity of medico-administrative data related to amyotrophic lateral sclerosis in France: A population-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 24-31. | 1.1 | 9 |
| 64 | Residential exposure to ultra high frequency electromagnetic fields emitted by Global System for Mobile (GSM) antennas and amyotrophic lateral sclerosis incidence: A geo-epidemiological population-based study. Environmental Research, 2019, 176, 108525. | 3.7 | 9 |
| 65 | Increased resting energy expenditure compared with predictive theoretical equations in amyotrophic lateral sclerosis. Nutrition, 2020, 77, 110805. | 1.1 | 9 |
| 66 | Familial clustering of primary lateral sclerosis and amyotrophic lateral sclerosis: Supplementary evidence for a continuum. European Journal of Neurology, 2021, 28, 2780-2783. | 1.7 | 9 |
| 67 | Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq1 1 0.784314 rgBT /Overloc<br>821-831. | 4.9 | 9 |
| 68 | Primary progressive aphasias associated with C9orf72 expansions: Another side of the story. Cortex, 2021, 145, 145-159. | 1.1 | 9 |
| 69 | First assessment at home of amyotrophic lateral sclerosis (ALS) patients by a nutrition network in the French region of Limousin. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 538-543. | 2.3 | 8 |
| 70 | Phenotypic and genotypic studies of ALS cases in ALS-SMA families. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 432-437. | 1.1 | 8 |
| 71 | Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism and Related Disorders, 2019, 60, 138-145. | 1.1 | 7 |
| 72 | SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. Brain, 2021, 144, 2798-2811. | 3.7 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Comparison of the ability of the Kingâ€™s and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 1-9. | 1.1 | 6 |
| 74 | Gastrostomies et maladies neuromusculaires. Nutrition Clinique Et Metabolisme, 2000, 14, 142-148. | 0.2 | 5 |
| 75 | Validity of death certificates in the identification of cases of amyotrophic lateral sclerosis (ALS) in the Limousin region, France. A population-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 228-234. | 1.1 | 5 |
| 76 | Amyotrophic lateral sclerosis mortality rates among ethnic groups in a predominant admixed population in Latin America: a population-based study in Ecuador. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 404-412. | 1.1 | 4 |
| 77 | Early onset Parkinsonism associated with an intronic SOD1 mutation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 315-317. | 2.3 | 3 |
| 78 | Vitamin D status among patients with drug-resistant and non-drug-resistant epilepsy. International Journal for Vitamin and Nutrition Research, 2020, 90, 205-209. | 0.6 | 3 |
| 79 | Spirometerâ€dependence of vital capacity in ALS: Validation of a portable device in 52 patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 239-245. | 2.3 | 2 |
| 80 | Troubles nutritionnels lors de la sclÃ©rose latÃ©rale amyotrophique (SLA). Nutrition Clinique Et Metabolisme, 2011, 25, 205-216. | 0.2 | 2 |
| 81 | Some new proposals for the classification of inherited myopathies. Journal of the Neurological Sciences, 2018, 391, 118-119. | 0.3 | 2 |
| 82 | What can we do for ALS patients with low vital capacity needing a digestive access for enteral nutrition?. Clinical Nutrition, 2006, 25, 705. | 2.3 | 1 |
| 83 | Nutrition parentÃ©rale et sclÃ©rose latÃ©rale amyotrophique (SLA). Nutrition Clinique Et Metabolisme, 2019, 33, 139-144. | 0.2 | 0 |
| 84 | Reply to the letter from Gazulla. European Journal of Neurology, 2022, 29, e3-e4. | 1.7 | 0 |
| 85 | ABNORMAL PHOSPHORYLATION OF TAU PROTEIN IN PRIMARY NEURONAL CULTURES: A CONFOCAL MICROSCOPY STUDY. Biology of the Cell, 1993, 79, 279-279. | 0.7 | 0 |